Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial

American Journal of Ophthalmology (May 2021)
David Clark, Bill Cavanagh, Alan L. Shields, Paul Karpecki, John Sheppard, Todd C. Brady